A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

Summary

The objective of this study is to investigate the safety and efficacy of aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over a period of 52 weeks in subjects who complete a short-term treatment study of pediatric patients (aged 13-17 years) with schizophrenia (031-09-003 study).

Timeline

Start

2010-08

Primary completion

2015-11

Completion

2015-11

Drugs

Indications